LAVA Therapeutics NVNASDAQ:LVTX
- LAST PRICE3.0699
- TODAY'S CHANGE (%)-0.0401 (-1.2894%)
- Bid / Lots3.0400/ 30
- Ask / Lots3.0700/ 4
- Open / Previous Close3.1500 / 3.1100
- Day Range
- 52 Week Range
- Volume24,710
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LVTX |
|---|---|---|
| 09:32 ET | 102 | 3.15 |
| 09:36 ET | 140 | 3.14 |
| 09:39 ET | 177 | 3.17 |
| 09:41 ET | 468 | 3.1402 |
| 09:43 ET | 100 | 3.15 |
| 09:48 ET | 1518 | 3.15 |
| 09:56 ET | 1227 | 3.15 |
| 10:03 ET | 1000 | 3.1501 |
| 10:21 ET | 1330 | 3.0701 |
| 10:24 ET | 300 | 3.08 |
| 10:28 ET | 900 | 3.1 |
| 10:35 ET | 117 | 3.104 |
| 10:39 ET | 101 | 3.0782 |
| 10:55 ET | 1000 | 3.105 |
| 11:02 ET | 200 | 3.13 |
| 11:22 ET | 900 | 3.0999 |
| 11:33 ET | 100 | 3.085 |
| 11:42 ET | 146 | 3.096 |
| 11:56 ET | 194 | 3.0811 |
| 11:58 ET | 146 | 3.0976 |
| 12:03 ET | 350 | 3.0989 |
| 12:12 ET | 350 | 3.1 |
| 12:18 ET | 2342 | 3.105 |
| 12:23 ET | 3657 | 3.08 |
| 12:27 ET | 787 | 3.07 |
| 12:39 ET | 1300 | 3.05 |
| 01:15 ET | 721 | 3.0401 |
| 02:27 ET | 100 | 3.055 |
| 02:38 ET | 2000 | 3.0503 |
| 03:02 ET | 600 | 3.0699 |
May 6, 2024
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference, from 4:05PM ET on Monday May 06, 2024 by Dow Jones
4:05PM ET on Monday May 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LAVA Therapeutics NV | 81.8M | -1.9x | --- |
Cue Biopharma Inc | 93.2M | -1.5x | --- |
Affimed NV | 79.7M | -0.7x | --- |
Kronos Bio Inc | 63.1M | -0.5x | --- |
Jaguar Health Inc | 85.5M | -0.1x | --- |
Kezar Life Sciences Inc | 59.5M | -0.6x | --- |
Company Information
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Contact Information
- Headquarters
- Yalelaan 60UTRECHT, Netherlands 3584 CM
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Kapil Dhingra
- President, Chief Executive Officer, Management Director
- Stephen Hurly
- Chief Financial Officer
- Edward Smith
- Executive Vice President Head of Research and Development
- Paul Parren
- Chief Scientific Officer
- Hans Van Der Vliet
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $81.8M |
|---|---|
Revenue (TTM) | $6.8M |
Shares Outstanding | 26.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.58 |
Book Value | $1.95 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 12.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -638.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
